FMS樣酪氨酸激酶3(Flt3)重組蛋白
Recombinant FMS Like Tyrosine Kinase 3 (Flt3)
CD135; STK1; FLK2; Fms-Related Tyrosine Kinase 3; Stem Cell Tyrosine Kinase 1; FL Cytokine Receptor; Fetal Liver Kinase-2
- 編號(hào)RPA039Mu01
- 物種Mus musculus (Mouse,小鼠) 相同的名稱,不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位細(xì)胞膜, 內(nèi)質(zhì)網(wǎng)腔
- 預(yù)測分子量27.5kDa
- 實(shí)際分子量27kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Lys335~Ser544 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)8.3
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1099 ¥ 2748 ¥ 5496 ¥ 16488 ¥ 41220
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Mus musculus (Mouse,小鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA039Mu01 | FMS樣酪氨酸激酶3(Flt3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA039Mu01 | FMS樣酪氨酸激酶3(Flt3)多克隆抗體 | WB; IHC; ICC; IP. |
LAA039Mu71 | FMS樣酪氨酸激酶3(Flt3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Frontiers in physiology | Alpha-1 Antitrypsin Prevents the Development of Preeclampsia Through Suppression of Oxidative Stress [pubmed:27303303] |
PLoS One | Evaluation of surfactant proteins A, B, C, and D in articular cartilage, synovial membrane and synovial fluid of healthy as well as patients with osteoarthritis and?… [Pubmed: 30235245] |
Bioscience Reports | N-Acetylcysteine inhalation improves pulmonary function in patients received Liver Transplantation. [Doi: 10.1042/BSR20180858] |
Molecular Neurobiology | Elevated levels of multifunctional surfactant proteins in cerebrospinal fluid are associated with signs of increased cerebrospinal fluid flow in cranial magnetic?… [Doi: 10.1007/s12035-017-0835-5] |
Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
留言咨詢